- Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial - (https://pubmed.ncbi.nlm.nih.gov/16801576/ )
- Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy - (https://pubmed.ncbi.nlm.nih.gov/18447661/)
- Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus - (https://pubmed.ncbi.nlm.nih.gov/8312678/ )
- Epalrestat, an aldose reductase inhibitor, in diabetic neuropathy: An Indian perspective - (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2771994/)
It inhibits the enzyme aldose reductase and reduces the level of sorbitol, which damages the nerves.
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak with a healthcare professional.
Restat (50mg) - Grownbury Pharmaceuticals Pvt. Ltd.
Restat (50mg) Tablet
Generic : Epalrestat
Substitute/Alternative Medication to Restat (50mg)
When is Restat (50mg) prescribed?
It is prescribed for -